On Jul. 14, 2023, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental new drug application for the use of Vekluryﾮ (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury was the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease.

More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease and are at increased risk of COVID-19 related morbidity and mortality.